SCHEDULE 1Modifications to the 2013 Regulations for pre-exit day cases
1
The modifications of the 2013 Regulations referred to in regulation 16 are that those Regulations are to be read as if—
a
in regulation 2 (interpretation)—
i
in the definition of “resident patient”, for “the United Kingdom is” there were substituted “immediately before exit day the United Kingdom was”;
ii
in the definition of “visiting patient”, for “a member State other than the United Kingdom is” there were substituted “immediately before exit day a member State other than the United Kingdom was”;
b
in the heading to regulation 5 (national contact point: information about treatment in another member State), for “another member State” there were substituted “a member State”;
c
in regulation 5—
i
for references to “other member States” there were substituted “member States”;
ii
for the reference to “another member State” there were substituted “a member State”;
d
regulation 5A (National Contact Point: information about prescriptions intended to be used in another member State) were omitted;
e
for regulation 6(1) (National Contact Point: cross-border co-operation) there were substituted—
1
In so far as it considers it appropriate for the purposes of giving effect to regulation 16 of the National Health Service (Cross-Border Healthcare and Miscellaneous Amendments etc) (EU Exit) Regulations 2019, the NCP must co-operate with the national contact points in member States and any other national contact points established in the United Kingdom.
f
regulation 7 (National Contact Point: duty to consult) were omitted;
g
in regulation 12—
i
in paragraph (2) for “P is” there were substituted “immediately before exit day P was”;
ii
in paragraph (2)(a), for “is resident” there were substituted “was resident”;
iii
in paragraph (2)(b), for “is the competent member State” there were substituted “was the competent member State”;
iv
in paragraph (4)(b) at the end there were inserted “as it had effect immediately before exit day”;
h
the schedule (elements that must be included in prescriptions intended to be used in another member State) were omitted.